Outcomes after anticoagulation-related intracranial bleeding in patients who do and do not resume anticoagulation therapy
| Study . | Indication for anticoagulation . | Anticoagulant . | Follow-up period . | HR-TE (95% CI) . | HR-recurrent ICH (95% CI) . | HR all-cause mortality (95% CI) . |
|---|---|---|---|---|---|---|
| Kuramatsu 2015, N = 71917 | AF, VTE, MVR, Other | VKA | 1-y | NR* | NR† | 0.26 (0.13-0.53)‡ |
| Witt 2015, N = 16018 | AF, VTE, MVR, Other | Warfarin | 1-y | 0.28 (0.06-1.27)§ | 0.47 (0.10-2.30)§ | 0.76 (0.30-1.89)¶ |
| Nielsen 2015, N = 175219 | AF | VKA, DOAC | 1-y | 0.59 (0.33-1.03)¶ | 0.91 (0.56-1.49)¶ | 0.55 (0.37-0.82)¶ |
| Antiplatelet therapy | 0.98 (0.65-1.49)¶ | 0.60 (0.37- 1.03)¶ | 0.90 (0.67-1.21)¶ |
| Study . | Indication for anticoagulation . | Anticoagulant . | Follow-up period . | HR-TE (95% CI) . | HR-recurrent ICH (95% CI) . | HR all-cause mortality (95% CI) . |
|---|---|---|---|---|---|---|
| Kuramatsu 2015, N = 71917 | AF, VTE, MVR, Other | VKA | 1-y | NR* | NR† | 0.26 (0.13-0.53)‡ |
| Witt 2015, N = 16018 | AF, VTE, MVR, Other | Warfarin | 1-y | 0.28 (0.06-1.27)§ | 0.47 (0.10-2.30)§ | 0.76 (0.30-1.89)¶ |
| Nielsen 2015, N = 175219 | AF | VKA, DOAC | 1-y | 0.59 (0.33-1.03)¶ | 0.91 (0.56-1.49)¶ | 0.55 (0.37-0.82)¶ |
| Antiplatelet therapy | 0.98 (0.65-1.49)¶ | 0.60 (0.37- 1.03)¶ | 0.90 (0.67-1.21)¶ |
NR, not reported.
Resumed VKA, 9/172 (5.2%) vs did not resume VKA, 82/547 (15.0%); P < .001.
Resumed VKA, 14/172 (8.1%) vs did not resume VKA, 36/547 (6.6%)—also included extracranial bleeding events; P = 0.48.
Propensity score-matched AF cohort.
Not adjusted because of small number of events.
Adjusted analysis.